Researching COVID to enhance recovery (RECOVER) pediatric study protocol: Rationale, objectives and design

Importance: The prevalence, pathophysiology, and long-term outcomes of COVID-19 (post-acute sequelae of SARS-CoV-2 [PASC] or “Long COVID”) in children and young adults remain unknown. Studies must address the urgent need to define PASC, its mechanisms, and potential treatment targets in children and young adults. Observations: We describe the protocol for the Pediatric Observational Cohort Study of the NIH’s REsearching COVID to Enhance Recovery (RECOVER) Initiative. RECOVER-Pediatrics is an observational meta-cohort study of caregiver-child pairs (birth through 17 years) and young adults (18 through 25 years), recruited from more than 100 sites across the US. This report focuses on two of five cohorts that comprise RECOVER-Pediatrics: 1) a de novo RECOVER prospective cohort of children and young adults with and without previous or current infection; and 2) an extant cohort derived from the Adolescent Brain Cognitive Development (ABCD) study (n=10,000). The de novo cohort incorporates three tiers of data collection: 1) remote baseline assessments (Tier 1, n=6000); 2) longitudinal follow-up for up to 4 years (Tier 2, n=6000); and 3) a subset of participants, primarily the most severely affected by PASC, who will undergo deep phenotyping to explore PASC pathophysiology (Tier 3, n=600). Youth enrolled in the ABCD study participate in Tier 1. The pediatric protocol was developed as a collaborative partnership of investigators, patients, researchers, clinicians, community partners, and federal partners, intentionally promoting inclusivity and diversity. The protocol is adaptive to facilitate responses to emerging science. Conclusions and Relevance: RECOVER-Pediatrics seeks to characterize the clinical course, underlying mechanisms, and long-term effects of PASC from birth through 25 years old. RECOVER-Pediatrics is designed to elucidate the epidemiology, four-year clinical course, and sociodemographic correlates of pediatric PASC. The data and biosamples will allow examination of mechanistic hypotheses and biomarkers, thus providing insights into potential therapeutic interventions.


Funding
This research was funded by the National Institutes of Health (NIH) Agreement OTA OT2HL161847 as part of the Researching COVID to Enhance Recovery (RECOVER) research Initiative.

Competing interests
Brett Anderson reported receiving direct support for work not related to RECOVER work/publications from Genentech and the National Institute of Allergy and Immunology.
Walter Dehority reported receiving grant support from Merck and participating in research for the Moderna COVID-19 pediatric vaccine trial and the Pfizer Paxlovid trial.
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted May 12, 2023. ; https://doi.org/10.1101/2023.04.27.23289228 doi: medRxiv preprint Alex Fiks reported receiving support from NJM insurance and personal consulting fees not related to this paper from Rutgers University and the American Academy of Pediatrics.
Ashraf Harahsheh reported serving as a scientific advisory board member unrelated to this paper for OP2 DRUGS. Medicines, in a capacity unrelated to RECOVER work/publications. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted May 12, 2023. ; https://doi.org/10.1101/2023.04.27.23289228 doi: medRxiv preprint Abstract Importance: The prevalence, pathophysiology, and long-term outcomes of COVID-19 (postacute sequelae of SARS-CoV-2 [PASC] or "Long COVID") in children and young adults remain unknown. Studies must address the urgent need to define PASC, its mechanisms, and potential treatment targets in children and young adults.
Observations: We describe the protocol for the Pediatric Observational Cohort Study of the NIH's REsearching COVID to Enhance Recovery (RECOVER) Initiative. RECOVER-Pediatrics is an observational meta-cohort study of caregiver-child pairs (birth through 17 years) and young adults (18 through 25 years), recruited from more than 100 sites across the US. This report focuses on two of five cohorts that comprise RECOVER-Pediatrics: 1) a de novo RECOVER prospective cohort of children and young adults with and without previous or current infection; and 2) an extant cohort derived from the Adolescent Brain Cognitive Development (ABCD) study (n=10,000). The de novo cohort incorporates three tiers of data collection: 1) remote baseline assessments (Tier 1, n=6000); 2) longitudinal follow-up for up to 4 years (Tier 2, n=6000); and 3) a subset of participants, primarily the most severely affected by PASC, who will undergo deep phenotyping to explore PASC pathophysiology (Tier 3, n=600). Youth enrolled in the ABCD study participate in Tier 1. The pediatric protocol was developed as a collaborative partnership of investigators, patients, researchers, clinicians, community partners, and federal partners, intentionally promoting inclusivity and diversity. The protocol is adaptive to facilitate responses to emerging science.
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
Nearly 100 million people have been diagnosed with COVID-19 in the United States (US), with nearly 16 million children [1]. Although it is estimated that between 10% and 30% of adults experience persistent symptoms from COVID-19 [2], termed post-acute sequelae of SARS-CoV-2 (PASC) or Long COVID, the prevalence in children is less well-established [3,4]. As an emerging illness, the absence of universally-accepted PASC definitions in children challenge the elucidation of its epidemiology.
Unique challenges in understanding PASC symptoms in children have likely contributed to the limited evidence. Given that young children might not be able to articulate symptoms, studies must rely on caregiver interpretation. In addition, manifestation of symptoms may vary substantively across stages of physiological, emotional, and cognitive development [5]. As the medical community shifts from managing serious acute disease to addressing long-term . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The pandemic began with a misconception that children were spared [6]. We now recognize that children and families are greatly impacted during both acute and chronic phases [7-10]. One distinct manifestation in children was recognized in April 2020; now called Multisystem Inflammatory Syndrome in Children (MIS-C) [11]. This debilitating hyperinflammatory syndrome has impacted over 9,000 children and young adults in the US [12], and represents a distinct post-acute syndrome that is typically recognizable in clinical practice. Other more chronic manifestations of PASC are challenging to characterize and identify. Furthermore, children with PASC may present with different symptoms and greater mental health concerns than adults [1,[13][14][15][16][17][18][19]. Additional phenotypes of childhood PASC are being reported, including phenotypes similar to postural orthostatic tachycardia syndrome (POTS), myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), postintensive care unit syndrome, and potentially many others [20][21][22]. Therefore, a compelling rationale exists to invest resources and effort to study PASC in children. The NIH's REsearching COVID to Enhance Recovery (RECOVER) Initiative responded by bringing together researchers, communities, and families in a systematic study of PASC in children [23]. Evidence that leads to improved health trajectories of children with PASC, could have population-level health impacts for decades to come.

Study rationale
RECOVER has established the Pediatric Observational Cohort Study (RECOVER-Pediatrics), which is a combined retrospective and prospective longitudinal study, including five distinct . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

Overview of study design
RECOVER-Pediatrics is a longitudinal, observational meta-cohort study of children and young adults (ages birth through 25 years) and their caregivers, recruited from healthcare-and community-based settings in more than 100 sites throughout the US, including Puerto Rico.
Those with and without a history of a SAR-CoV-2 infection are included. For those 17 years or . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)   Figure 1 shows a tiered overview of 2 of the 5 cohorts included in the meta-cohort (de novo RECOVER prospective cohort and ABCD), their participation in the three study tiers, and their targeted sample sizes (see Study Participants). Children and young adults ages newborn through 25 years old will be enrolled in the meta-cohort at Tier 1 for the de novo RECOVER prospective cohort (more than 6,000 from birth through 25 years old, including those with and without history of infection), and from ABCD (up to 10,000 adolescents with and without history of infection). All children and young adults enrolled in the study complete a baseline assessment . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted May 12, 2023. ; https://doi.org/10.1101/2023.04.27.23289228 doi: medRxiv preprint (Tier 1). Percentages shown indicate random sampling proportions. Children and young adults without history of infection are assigned at random with prespecified proportions to the acute and post-acute arms. All children and young adults with history of infection who enroll into the acute arm and those without a history of infection who are randomized to the acute arm are asked to complete assessments at 2, 4, and 8 weeks. Following a promotion algorithm (Table 2), children and young adults in Tier 1 will be selected to be promoted to Tier 2, which includes assessments at 2-6, 12, 24, 36, and 48 months after enrollment. 600 children and young adults with history of infection, selected from Tier 2, will complete more intensive Tier 3 assessments at 12 and 24 months after enrollment. *Children and young adults with history of infection who enroll in the post-acute arm ("postacute infected", n=4,000) are stratified into High, Medium, and Low probability of PASC groups based on a combination of past Long COVID diagnoses, Tier 1 Global PROMIS health measures, and symptom survey screener responses. Then, 100% of the high probability group, 50% of the medium probability group, and 20% of the low probability group are promoted at random to Tier 2. Since the distribution of these probability groups is unknown a priori, sample sizes are not specified for each category. Overall, the number of children and young adults who progress to Tier 2 will be less than the initial post-acute infected sample size, but the total target sample size for infected children and young adults in Tier 2 is 5,400. ** In order to achieve a sample of 5,400 children and young adults with history of infection in Tier 2 that is skewed towards those with greater likelihood of having PASC, additional children and young adults will be recruited from Long COVID clinics and subspecialty services to complete both Tier 1 and Tier 2 assessments.
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted May 12, 2023. ; https://doi.org/10.1101/2023.04.27.23289228 doi: medRxiv preprint RECOVER-Pediatrics is structured in a sequential fashion with three Tiers of data collection.
Participants may be enrolled initially into Tier 1, which consists of a broad screening of health using remote surveys and biospecimen collection. Participants may subsequently progress to Tier 2, which includes a detailed review of health collected longitudinally for up to four years, using a combination of remote surveys and in-person assessments of biological and psychosocial data. In order to achieve the sample size required for Tier 2 assessments, other study participants will be recruited who present with a high probability of having PASC, such as those directly recruited from a clinic that focuses on Long COVID or presenting with a physician diagnosis of PASC.
These participants will receive Tier 1 assessments and progress directly to Tier 2. Finally, in Tier 3, a subset of children and young adults most severely affected by PASC will undergo deep phenotyping with more intensive assessments to study PASC pathophysiology.
RECOVER-Pediatrics Tier 1 assessments aim to characterize the prevalence and incidence of new onset or worsening of sustained COVID-related symptoms (aim 1) and to gain a comprehensive understanding of the impact of exposure to a SARS-CoV-2 infection on broad physical, behavioral and mental health (aim 2). Tier 2 facilitates studying the natural history of PASC symptoms and potential recovery over time (aim 2). Child, household, and caregiver factors gathered in Tier 1, such as social determinants of health and prior health conditions, will be assessed to determine how they increase the risk of or protect against specific clinical outcomes (aim 3). Finally, Tier 3 data investigates long-term effects on multiple organ systems and child development (aim 4). Additionally, integration of Tier 1 and Tier 2 data will allow . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted May 12, 2023. ; https://doi.org/10.1101/2023.04.27.23289228 doi: medRxiv preprint investigation of COVID-disease exposures and experiences which may be responsible for the clinical patterns observed in Tier 3.
The pediatric protocol was designed through collaboration across key stakeholders, including patients, caregivers, researchers, clinicians, community partners, and federal partners, fostering a patient-centered approach and promoting inclusivity and diversity. The pediatric protocol is adaptive to facilitate the changes needed in light of emerging science and the evolving pandemic. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted May 12, 2023. ; https://doi.org/10.1101/2023.04.27.23289228 doi: medRxiv preprint 10 hubs that manage ~100 sites (Supplemental Table 1). NYU Grossman School of Medicine serves as the sIRB for sites without prior reliance agreements.

Recruitment, consent, and screening strategies
The de novo RECOVER prospective cohort study is recruiting participants from healthcare-and community-based settings. Healthcare-based recruitment involves local media, text messaging, hospital websites, COVID registries, and partnerships with pediatric practices, nurse hotlines, or emergency departments. Community-based recruitment includes partnering with community health workers, school nurses, sports coaches, health fairs, and a mobile van to access rural communities. Participants can also join by self-referral through the RECOVER website, or in response to plain language and picture-based recruitment materials in both English and Spanish, which were developed with community input and using health literacy principles [29].
Eligible dyads complete an informed consent or assent process at enrollment for Tiers 1 and 2 (in-person or via electronic informed consent [e-consenting]). Young adults, aged 18 through 25 years old, sign their own informed consent. Tier 3 consent forms will only be completed when testing is offered.
In ABCD, 11,880 children aged 9-10 years old were recruited from community and school sites to participate in a 10-year study with the goal of understanding neurocognitive development during adolescence [24, 25, 30]. All ABCD participants are being contacted and offered enrollment into RECOVER-Pediatrics.

Eligibility criteria
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted May 12, 2023. A primary caregiver, defined as an individual responsible for the enrolled child or young adult who resides in the same household, such as biological or nonbiological family member, is invited to enroll.
The primary exclusion criterion is any child or young adult with co-morbid illness with expected survival of less than 2 years. There is no limit to the number of children or young adults who can be enrolled from a single household. See supplemental tables for detailed eligibility criteria, definitions of analytic groups, and the World Health Organization Criteria (Supplement Tables   2, 3, and 4, respectively).

Study participants
Recruitment is striving for a diverse sample that generally represents the US population, and encourages participation from rural or medically underserved communities, non-English speaking participants, and non-hospitalized participants with an acute COVID-19 infection.
Participants are compensated for completing assessments and reimbursed for excess travel.
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted May 12, 2023. ; https://doi.org/10.1101/2023.04.27.23289228 doi: medRxiv preprint At least 6,000 participants will be recruited into the de novo cohort (Figure 1). Children and young adults with history of infection are classified into one of two study arms (acute arm vs. post-acute arm), based on their history of SARS-CoV-2 infection and infection dates. The acute arm includes 800 children and young adults whose most recent SARS-CoV-2 infection was 30 days or less prior to enrollment. The post-acute arm includes 4,000 children and young adults whose most recent SARS-CoV-2 infection was greater than 30 days prior to enrollment. In the group without a history of infection, 1,200 children and young adults will be randomly assigned to follow either the acute (200, or 17%) or post-acute (1,000 or 83%) arm of the protocol.
Additional children and young adults will be recruited from Long COVID clinics and other subspecialty services in order to achieve Tier 2 sample size targets (see Timing of Study Assessments).
Up to 10,000 participants will also be recruited from the ABCD cohort.

Timing of study assessments
The assessments for the de novo cohort consists of three tiers, which vary in timing, collection methods and intensity.
Tier 1 (baseline visit for all participants) includes a single visit that is completed either via selfadministration (remote and electronic) or research staff-assisted collection (e.g., telephone, videoconference, or in-person).
Tier 2 (follow-up visits) includes five longitudinal in-person visits at 2 to 6-, 12-, 24-, 36-and 48-months post-enrollment. The children and young adults followed longitudinally in Tier 2 are selected based on a sampling scheme that prioritizes the acute arm as well as children and youth . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted May 12, 2023. ; https://doi.org/10.1101/2023.04.27.23289228 doi: medRxiv preprint in the post-acute arm with a greater likelihood of having PASC. Promotion to Tier 2 occurs as follows: 1) All children/young adults in the acute arm with or without history of infection will be promoted; 2) children/young adults in the post-acute arm with a history of infection will be promoted at a rate dependent on their likelihood of PASC based on prior Long COVID diagnoses, Tier 1 PROMIS global health measure responses [32][33][34], and symptoms screener survey responses [16,35] (Table 1); and 3) 40% of children/young adults without known infection in the post-acute arm, selected at random, will be promoted. In addition to promoting children and young adults from Tier 1, children and young adults will also be recruited from Long COVID clinics and subspecialty services to achieve the target sample size in Tier 2 of 6,000. These children and young adults will complete both Tier 1 and Tier 2 assessments. See Table 2 for a full description of the promotion algorithm.
Children and young adults in the acute arm with a history of infection will also complete remote assessments at 2, 4, and 8 weeks after their infection onset, with additional in-person assessments at 8 weeks. Children and young adults in the acute arm without history of infection will complete the same assessments, timed relative to their enrollment date. All ABCD youth are eligible to participate in RECOVER Tier 1, and can be referred to a de novo cohort site to participate in Tiers 2 and 3, if geographically feasible. Main categories of data . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted May 12, 2023. ; https://doi.org/10.1101/2023.04.27.23289228 doi: medRxiv preprint Data collected for the de novo and ABCD cohorts are described below (Table 3).
Surveys include validated surveys with NIH common data elements, as available, informed by expert opinion (Supplemental Table 5 [16,35] (Table 1), with respondents asked whether a specific problem or symptom is/was present for at least 4 weeks since the beginning of the COVID-19 pandemic and, for respondents with a history of infection, if the symptoms started before or after their infection.
Clinical assessments are completed at in-person Tier 2 visits across overarching domains of physical growth, physical health, neurocognition, and neurobehavioral function (Supplemental . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Biospecimens are collected across all Tiers using kits designed specifically for each visit, timepoint, and participant age ( Table 5; Supplemental Table 6). Tier 1 biospecimens consist of saliva and whole blood. Kits are shipped to homes for remote collection. Child and primary caregivers provide both saliva and blood; the other biological parent when available provides only saliva. Saliva is collected using Oragene devices (OGR-600) and banked for future DNA analysis. Whole blood is collected using a TASSO M20 device [65], which collects capillary blood using 4 volumetric sponges that each hold 17.5µL of blood (70 µL total). One sponge is used for SARS-CoV-2 spike and nucleocapsid antibody testing and remaining sponges are banked for future use.
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted May 12, 2023. ; https://doi.org/10.1101/2023.04.27.23289228 doi: medRxiv preprint Tier 2 acute biospecimens include saliva (Oragene OGR-600) and whole blood collections. All post-acute Tier 2 biospecimens consist of whole blood. The maximum amount of blood drawn at a single visit is age dependent. Whole blood is collected using serum separator tube (SST) and Ethylenediaminetetraacetic tube acid (EDTA) across all ages above 24 months and an additional cell preparation tube (CPT) is included at participants 6 years of age and older.
Tier 3 biospecimens consist of whole blood, sputum, swabs (e.g., skin, nasal, oral), urine and stool. Collection of Tier 3 biospecimens is limited to children ages 3 years and older (maximum allowable volume is age dependent).

Statistical methods
We will estimate the proportion of children and young adults experiencing new onset or worsening of each symptom (incidence), stratified by age (0-2, 3-5, 6-12, 13-17, 18-25 years), over time. Prevalence within the recruited population will be estimated by calculating the point prevalence of each symptom at each 3-month interval since infection by calculating the proportion of children and young adults who are currently experiencing each symptom at each study visit. The excess burden of each symptom due to infection will be assessed by calculating differences in incidence and prevalence between children and young adults with and without an infection history. Odds ratios and relative risks for the association between infection and onset of each symptom will also be calculated, adjusting for sex in each age strata.
A preliminary case definition of PASC will be informed by using variable selection methods to identify which symptoms best differentiate children and young adults with and without an infection. The estimated associations obtained from regression models will be used to define a . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted May 12, 2023. With this definition of PASC, we will conduct regression analyses to evaluate whether the risk of PASC and PASC sub-types differs by multiple factors, including demographic, clinical, and caregiver characteristics, social determinants of health, SARS-CoV-2 infection and immunization history, symptom severity during the acute phase of SARS-CoV-2 infection, and therapeutic exposures. Among participants in Tier 2 who develop PASC, we will use time-toevent analyses to identify factors that influence time to recovery from PASC. To investigate biomarkers related to PASC, clinical laboratory assessments will be compared between children and young adults who do and do not develop PASC. Mediation analyses will also be used to study the pathways by which SARS-CoV-2 infection leads to the development of PASC.

Power calculations
Power calculations for the de novo cohort were performed prior to recruitment using a type 1 error rate of 0.01. With 4,800 infected and 1,200 uninfected children and young adults from both acute and post-acute arms in Tier 1, assuming the risk of a given symptom in the uninfected . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted May 12, 2023. ; https://doi.org/10.1101/2023.04.27.23289228 doi: medRxiv preprint group is 10%, we have 90% power to detect a difference as small as 4.1% in the frequency of that symptom between groups.
In Tier 2, given the sampling and promotion framework described in Timing of Study Assessments, our sample with longitudinal follow-up will be skewed towards those who are more likely to have PASC. Following development of a definition of PASC, we consider the scenario in which we assume that of the 5,400 children and young adults with a history of infection in Tier 2, 3,600 meet PASC criteria and 1,800 do not. For a hypothetical risk factor with 50% prevalence in the PASC-group, we have 90% power to detect an odds ratio as small as 1.25 for the odds of PASC for those with the risk factor versus those without. For a factor with 25% prevalence in the PASC-negative group, the minimum detectable odds ratio is 1.29. In our Tier 3 sample of 600 children and young adults with history of infection (which includes additional data on biomarkers), assuming the sample has 400 with PASC and 200 without PASC, for a marker with 10% prevalence in the PASC-group, we have 90% power to detect an odds ratio as small as 2.60 for PASC.

Discussion
The overall goal of RECOVER-Pediatrics is to improve our understanding of recovery after SARS-CoV-2 infection, with a focus on the prevalence, natural history, and pathogenesis of PASC in children and young adults. Successful completion should lead to formal characterization of pediatric PASC as its own syndrome. This is essential to develop diagnostic, treatment, and preventive strategies tailored to children's unique physiology.
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted May 12, 2023. ; https://doi.org/10.1101/2023.04.27.23289228 doi: medRxiv preprint RECOVER-Pediatrics is well positioned to ascertain the epidemiology, four-year clinical course, and sociodemographic contributions to pediatric PASC, with rich data and biosamples available to readily test further mechanistic hypotheses, establish biomarkers, and provide insights into potential therapies. The meta-cohort is designed to provide details that are not available in other large epidemiologic or electronic health records queries, including a dynamic study design that can be flexible and responsive as new variants arise, and as our understanding of the long-term effects of SARS-CoV-2 evolves. RECOVER-Pediatrics was designed to include a wide range of ages, and diverse socioeconomic, racial, ethnic and geographic populations to ensure that findings are generalizable, and provide equitable benefit for all.
The generation-defining nature of the COVID-19 pandemic will impact the life course of children in ways that we have yet to fully understand. The unprecedented scope of RECOVER-Pediatrics sets the stage for not only characterizing a new disorder that will impact children for years to come, but also for identifying and deploying solutions through its collaborations with investigators and communities across the country.
RECOVER-Pediatrics is expected to gather a rich data set that can be used to develop treatments for persons with Long COVID and provide guidelines for how to respond more quickly to prevent, reduce the consequences, and treat complications of future coronavirus outbreaks which are likely to emerge.

Disclaimer
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted May 12, 2023. ; https://doi.org/10.1101/2023.04.27.23289228 doi: medRxiv preprint Authorship has been determined according to ICMJE recommendations. The content is solely the responsibility of the authors and does not necessarily represent the official views of the RECOVER program, the NIH or other funders.

Acknowledgement
We would like to thank the National Community Engagement Group (NCEG), all patient, caregiver and community representatives, and all the participants enrolled in the RECOVER initiative.

Supporting information
The supporting information is provided in a supplemental appendix file.
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted May 12, 2023.  . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted May 12, 2023. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted May 12, 2023. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted May 12, 2023.  . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted May 12, 2023.  . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted May 12, 2023.

62.
Beery K, Beery N. Beery VMI: The Beery-Buktenica Developmental test of visual-motor integration with supplemental developmental tests of visual perception and motor coordination: Stepping stones age norms from birth to age six. administration, scoring, and teaching manual: . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

Symptoms being Assessed
General symptoms or problems Major Fever Feeling sleepy during the day a Fussy or cranky (crying a lot) b Low energy or not feeling strong enough to do things a Feeling very tired all day long a Feeling very tired after walking a Not wanting to eat (poor appetite) Lost weight or gained less than expected Lost height or grew less than expected

Minor
Trouble sleeping Hot and cold spells (feeling hot or cold for no reason) a Sweating more than normal Wanting to eat more than normal (increased appetite) Wanting to drink liquids more than normal (increased thirst) Gained weight more than expected Symptoms or problems in the eyes, ears, nose, and throat

Major
Light hurts your eyes a Change in hearing a Ringing in the ears a Change in smell a Loss of smell a Throat hurts (sore throat) a Loss of voice (sounding hoarse) Problems swallowing Change in how things taste c

Minor
Eyes look red Eyes are watery Eyes are dry Dark circles or color under the eyes Trouble seeing or blurry vision a Stuffy nose or runny nose Very dry mouth a Problems with teeth or gums Chapped lips Symptoms or problems involving the heart and lungs Dry cough Wet cough (brings up mucus) Barking cough Trouble breathing (breathing too fast) . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted May 12, 2023. Sore muscles or pain in the muscles a Body aches or pains Symptoms or problems involving the brain and nerves Major Headache c Feeling dizzy (feeling like the room is spinning) c Shakiness or tremors c Feeling tingling or 'pin-and-needles' in the hands and feet c Unable to move part of the body Problems with remembering things (memory) a Problems with focusing on things (concentration), sometimes called "brain fog" a Problems with talking a

Symptoms or problems involving feelings or behavior
Feeling sad or depressed c Feeling anxious or on edge c Feeling a lot of fear when being away from parent or caregiver b Feeling a lot of fear of specific things like spiders or being up high d Feeling a lot of fear about being with other children or adults d . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted May 12, 2023.  Acute arm At enrollment, 17% of the "uninfected" group were randomly assigned to participate in the acute arm of the study.

100%
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted May 12, 2023.  [16,35]. Not all symptoms are asked of all participants, as many are age-specific (e.g., fewer symptoms assessed for younger children) and sex-specific (e.g., menses related symptoms).
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)   . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted May 12, 2023. ; https://doi.org/10.1101/2023.04.27.23289228 doi: medRxiv preprint • 1 x 1 mL -ARUP • 1 x 2 mL -ARUP • 1 x 1.5 mL -PBC • 6 x 200 µL for . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted May 12, 2023. • TBD . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted May 12, 2023. ; https://doi.org/10.1101/2023.04.27.23289228 doi: medRxiv preprint a Sample volumes are age dependent: (newborn to under 6 years: maximum draw of 2 mL per kg of body weight; 6 to under 10 years: 25 mL; greater than 10 years old: 38 mL) b SST tube is collected and within 4 hours of collection the SST tube is centrifuged, serum is aliquoted and frozen locally at collection sites. Serum aliquots are batch shipped frozen on dry ice in monthly intervals and are banked for future research. c The EDTA tube is collected for all age groups and is processed for plasma, WBC, and RBC aliquots. A plasma aliquot is sent out for central testing. The other EDTA aliquot derivatives are frozen and banked for future research. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted May 12, 2023. ; https://doi.org/10.1101/2023.04.27.23289228 doi: medRxiv preprint